AYA cancer survivors treated with cardiotoxic therapies exhibit accelerated cardiac aging
Click Here to Manage Email Alerts
Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.
The cross-sectional study included 127 cancer survivors treated with anthracyclines or radiation for Hodgkin lymphoma or sarcoma as adolescents or young adults (AYAs).
A review of 424 echocardiograms from these individuals revealed significant differences between AYA cancer survivors and untreated individuals.
Ninety percent of AYA cancer survivors had two or more measures suggesting their hearts were at least 2 decades older than their chronological age, results showed. Survivors also exhibited an average of 4.2 measures reflective of accelerated cardiac aging.
Healio spoke with researcher Michelle A.T. Hildebrandt, PhD, associate professor in the department of lymphoma/myeloma at The University of Texas MD Anderson Cancer Center, about the findings and their potential clinical implications.
Collapse
Click Here to Manage Email Alerts